TNF Pharmaceuticals, Inc.
TNFA
$0.22
$0.02814.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -23.36M | -23.66M | -17.69M | -12.29M | -4.00M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.30M | 12.87M | 5.16M | -1.26M | -9.80M |
| Change in Net Operating Assets | -916.70K | 645.90K | 2.86M | 2.63M | 815.50K |
| Cash from Operations | -8.98M | -10.14M | -9.67M | -10.92M | -12.98M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.10M | -1.27M | -993.90K | 13.85M | 1.85M |
| Cash from Investing | -6.10M | -1.27M | -993.90K | 13.85M | 1.85M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 14.00M | 14.00M | 14.00M | 0.00 | 14.69M |
| Repurchase of Preferred Stock | -73.50K | -163.10K | -163.10K | -163.10K | -89.60K |
| Total Dividends Paid | -2.49M | -2.59M | -2.59M | -2.59M | -1.45M |
| Other Financing Activities | 0.00 | -77.10K | -145.20K | -145.20K | -77.10K |
| Cash from Financing | 12.57M | 12.31M | 11.11M | -2.89M | 13.07M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.51M | 894.00K | 442.20K | 37.10K | 1.93M |